House-Senate Versions Married In Latest User-Fee Bill, Up For July 12 House Debate
Differences between Senate and House Committee versions of the FDA Reauthorization Act passed in May and June to approve five-year device user-fee agreements have been smoothed over by committee staff and joined together in the latest version of the act. The bill has been placed on the House's calendar in anticipation of July 12 action to debate and approve the bill. Next steps in the Senate, meanwhile, remain to be seen.
[Editors' note: Follow progress with legislation impacting the device and diagnostics industry with Medtech Insight's US Congress Tracker.]
The US House will take up a combined version of House and Senate FDA Reauthorization Act (FDARA) bills to approve the 2018-2022 device user-fee agreement on July 12. In addition to the core user-fee agreement (Also see "User-Fee Facts: 10 Key Medtech Details From US FDA Agreements" - Medtech Insight, 11 May, 2017
